- Home
- BLFS vs URGN Comparison
BLFS vs URGN Comparison
Compare BLFS & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLFS
- URGN
- Stock Information
- Founded
- BLFS 1987
- URGN 2004
- Country
- BLFS United States
- URGN United States
- Employees
- BLFS N/A
- URGN N/A
- Industry
- BLFS Medical/Dental Instruments
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- BLFS Health Care
- URGN Health Care
- Exchange
- BLFS Nasdaq
- URGN Nasdaq
- Market Cap
- BLFS 995.2M
- URGN 896.3M
- IPO Year
- BLFS 1989
- URGN 2017
- Fundamental
- Price
- BLFS $24.34
- URGN $19.71
- Analyst Decision
- BLFS Strong Buy
- URGN Strong Buy
- Analyst Count
- BLFS 7
- URGN 8
- Target Price
- BLFS $30.86
- URGN $27.75
- AVG Volume (30 Days)
- BLFS 584.6K
- URGN 1.3M
- Earning Date
- BLFS 08-07-2025
- URGN 08-07-2025
- Dividend Yield
- BLFS N/A
- URGN N/A
- EPS Growth
- BLFS N/A
- URGN N/A
- EPS
- BLFS N/A
- URGN N/A
- Revenue
- BLFS $93,468,000.00
- URGN $94,238,000.00
- Revenue This Year
- BLFS $21.22
- URGN $39.80
- Revenue Next Year
- BLFS $17.50
- URGN $108.94
- P/E Ratio
- BLFS N/A
- URGN N/A
- Revenue Growth
- BLFS 68.16
- URGN 10.85
- 52 Week Low
- BLFS $19.10
- URGN $3.42
- 52 Week High
- BLFS $29.55
- URGN $21.02
- Technical
- Relative Strength Index (RSI)
- BLFS 60.60
- URGN 62.57
- Support Level
- BLFS $22.22
- URGN $17.21
- Resistance Level
- BLFS $25.74
- URGN $20.55
- Average True Range (ATR)
- BLFS 1.22
- URGN 1.21
- MACD
- BLFS 0.44
- URGN -0.18
- Stochastic Oscillator
- BLFS 75.00
- URGN 66.92
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.